Volume 12, Number 3—March 2006
Perspective
Cost-effectiveness of West Nile Virus Vaccination
Armineh Zohrabian*
, Edward B. Hayes†, and Lyle R. Petersen†
, Edward B. Hayes†, and Lyle R. Petersen†
Table 1
Uniform distributions for each variable used in simulations to assess the cost-effectiveness of vaccination against West Nile virus (WNV)*
| Variable | Lower limit | Baseline | Upper limit |
|---|---|---|---|
| Probability of infection | 0.012 | 0.016 | 0.02 |
| Probability of symptomatic illness | 0.15 | 0.20 | 0.25 |
| Probability of symptomatic illness after vaccination† | 0.03 | 0.04 | 0.05 |
| Probability of neuroinvasive disease, given symptoms | 0.027 | 0.036 | 0.045 |
| Probability of death, given neuroinvasive disease | 0.07 | 0.09 | 0.11 |
| Probability of disability, given neuroinvasive disease | 0.26 | 0.35 | 0.44 |
| Cost of neuroinvasive disease | $20,625 | $27,500 | $34,375 |
| Cost of death (direct and indirect financial losses) | $150,000 | $200,000 | $250,000 |
| Cost of lifelong disability | $158,000 | $210,000 | $263,000 |
| Cost of uncomplicated WNV febrile illness | $750 | $1,000 | $1,250 |
| Cost of vaccination | $75 | $100 | $125 |
*Upper and lower limits are calculated as ±25% of the baseline values and rounded up.
†Baseline vaccine effectiveness is assumed to be 80%.
Page created: January 27, 2012
Page updated: January 27, 2012
Page reviewed: January 27, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.